In addition to its role in purine metabolism, our colleagues and we have used genetic, pharmacological, and immunological methods to demonstrate the therapeutical potential of CD39 as a potential “novel immune checkpoint”, as in tumor immunotherapy (68–72). Here, ENTPD1 is linked to neoplasm.